Peptide Synthesis

A peptide CDMO is a Contract Development and Manufacturing Organization that provides development, scale-up, and manufacturing services for peptide therapeutics. These organizations support pharmaceutical and biotech companies by delivering custom peptide synthesis, process development, purification, and analytical testing to advance programs from clinical development to commercial production.

Peptide synthesis services support process development, analytical development & characterization, and scale-up & manufacturing of synthetic peptides used as therapeutic drugs.

Custom peptide synthesis services typically use solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), or hybrid approaches that combine both technologies. SPPS is often used for rapid early-stage peptide development, while LPPS and hybrid synthesis strategies are more flexible for scale-up as the process advances to larger-scale and commercial production.

A peptide CDMO supports scale-up by developing robust synthesis and purification processes that maintain yield, purity, and reproducibility as production volumes increase. 

Chromatography is critical for achieving the purity required for therapeutic peptides. Advanced purification methods such as reverse-phase chromatography and twin-column systems enable efficient downstream processing, helping manufacturers achieve high yield and purity across different scales of peptide production. 

Peptides require extensive analytical testing to confirm identity, purity, potency, and stability. Integrated analytical services support method development, validation, and release testing to ensure regulatory compliance and consistent product quality throughout development and commercial production.

Peptide manufacturing can be complex due to scale-up challenges, purification requirements, and regulatory expectations. Achieving high purity and yield often requires specialized chromatography capabilities and integrated analytical testing to prevent bottlenecks and ensure reliable supply. 

Yes. Many peptide CDMOs provide scalable development and manufacturing services that support programs from early clinical stages through commercial production. Integrated capabilities in synthesis, purification, and analytical testing help streamline technology transfer and accelerate development timelines.